Irinotecan

Modify Date: 2025-08-20 16:21:15

Irinotecan Structure
Irinotecan structure
 Common Name Irinotecan
CAS Number 97682-44-5 Molecular Weight 586.678
Density 1.4±0.1 g/cm3 Boiling Point 873.4±65.0 °C at 760 mmHg
Molecular Formula C33H38N4O6 Melting Point N/A
MSDS N/A Flash Point 482.0±34.3 °C

 Use of Irinotecan


Irinotecan is a water soluble topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.

 Names

Name Irinotecan
Synonym More Synonyms

 Irinotecan Biological Activity

Description Irinotecan is a water soluble topoisomerase I inhibitor, preventing religation of the DNA strand by binding to topoisomerase I-DNA complex.
Related Catalog
Target

Topoisomerase I

In Vitro Irinotecan is a topoisomerase I inhibitor. Irinotecan inhibits the growth of LoVo and HT-29 cells, with IC50s of 15.8 ± 5.1 and 5.17 ± 1.4 μM, respectively, and induces similar amounts of cleavable complexes in both in LoVo and HT-29 cells[2]. Irinotecan suppresses the proliferation of human umbilical vein endothelial cells (HUVEC), with an IC50 of 1.3 μM[3].
In Vivo Irinotecan (CPT-11, 5 mg/kg) significantly inhibits the growth of tumors by intratumoral injection daily for 5 days, on two consecutive weeks in rats, and such effects also occur via continuous intraperitoneal infusion by osmotic minipump into mice. However, Irinotecan (10 mg/kg) shows no effect on the growth of tumor by i.p[1]. Irinotecan (CPT-11, 100-300 mg/kg, i.p.) apparently suppresses tumor growth of HT-29 xenografts in athymic female mice by day 21. The two groups of Irinotecan (125 mg/kg) plus TSP-1 (10 mg/kg per day) or Irinotecan (150 mg/kg) in combination TSP-1 (20 mg/kg per day) are nearly equally effective and inhibit tumor growth 84% and 89%, respectively, and both are more effective than Irinotecan alone at doses of 250 and 300 mg/kg[3].
Cell Assay Exponentially growing cells are seeded in 20 cm2 dishes with an optimal cell number for each cell line (20,000 for LoVo cells, 100,000 for HT-29 cells). They are treated 2 days later with increasing concentrations of irinotecan or SN-38 for one cell doubling time (24 h for LoVo cells, 40 h for HT-29 cells). After washing with 0.15 M NaCl, the cells are further grown for two doubling times in normal medium, detached from the support with trypsin-EDTA and counted in a hemocytometer. The IC50 values are then estimated as the drug concentrations responsible for 50% growth inhibition as compared with cells incubated without drug[2].
Animal Admin Irinotecan has been administered by intratumoral injection at 0.1 cc volume of the appropriate solution, for a doses of 5 mg/kg daily for 5 days, on two consecutive weeks, followed by a 7-days rest period, referred to as one cycle of therapy. Rats receive three cycles over a period of 8 weeks. Control animals receive 0.1 cc of sterile 0.9% sodium chloride solution by intratumoral injection in the same rule of administration as that of animals of group II[1].
References

[1]. Morales C, et al. Antitumoral effect of irinotecan (CPT-11) on an experimental model of malignant neuroectodermal tumor. J Neurooncol. 2002 Feb;56(3):219-26.

[2]. Pavillard V, et al. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines. Cancer Chemother Pharmacol. 2002 Apr;49(4):329-35. Epub 2002 Jan 30.

[3]. Allegrini G, et al. Thrombospondin-1 plus irinotecan: a novel antiangiogenic-chemotherapeutic combination that inhibits the growth of advanced human colon tumor xenografts in mice. Cancer Chemother Pharmacol. 2004 Mar;53(3):261-6. Epub 2003 Dec 5.

[4]. Dela Cruz FS, et al. A case study of an integrative genomic and experimental therapeutic approach for rare tumors: identification of vulnerabilities in a pediatric poorly differentiated carcinoma. Genome Med. 2016 Oct 31;8(1):116.

[5]. Huang MY, et al. Chemotherapeutic agent CPT-11 eliminates peritoneal resident macrophages by inducing apoptosis. Apoptosis. 2016 Feb;21(2):130-42.

 Chemical & Physical Properties

Density 1.4±0.1 g/cm3
Boiling Point 873.4±65.0 °C at 760 mmHg
Molecular Formula C33H38N4O6
Molecular Weight 586.678
Flash Point 482.0±34.3 °C
Exact Mass 586.279114
PSA 114.20000
LogP 4.35
Vapour Pressure 0.0±0.3 mmHg at 25°C
Index of Refraction 1.689
InChIKey UWKQSNNFCGGAFS-XIFFEERXSA-N
SMILES CCc1c2c(nc3ccc(OC(=O)N4CCC(N5CCCCC5)CC4)cc13)-c1cc3c(c(=O)n1C2)COC(=O)C3(O)CC
Storage condition 2-8°C

 Safety Information

Hazard Codes Xn
Risk Phrases 22
RTECS DW1061000

 Synthetic Route

 IrinotecanBioassay

View more

Name: Cytotoxicity against human DU145 cells by SRB assay
Source: ChEMBL
Target: DU-145
External Id: CHEMBL2215761
Name: Cytotoxicity against human KB cells by SRB assay
Source: ChEMBL
Target: KB
External Id: CHEMBL2215762
Name: Primary qHTS assay for inhibitors of alpha-synuclein gene (SNCA) expression
Source: NCGC
External Id: SNCA-p-activity-luciferase
Name: Cytotoxicity against human KBVIN cells by SRB assay
Source: ChEMBL
Target: NON-PROTEIN TARGET
External Id: CHEMBL2215760
Name: Cytotoxicity against human A549 cells by SRB assay
Source: ChEMBL
Target: A549
External Id: CHEMBL2215763
Name: Growth inhibition of human A549 cells after 72 hrs by XTT assay
Source: ChEMBL
Target: A549
External Id: CHEMBL1931030
Name: Growth inhibition of human MDA-MB-231 cells after 72 hrs by XTT assay
Source: ChEMBL
Target: MDA-MB-231
External Id: CHEMBL1931029
Name: Growth inhibition of human HepG2 cells after 72 hrs by XTT assay
Source: ChEMBL
Target: HepG2
External Id: CHEMBL1931032
Name: Growth inhibition of human H1299 cells after 72 hrs by XTT assay
Source: ChEMBL
Target: NON-PROTEIN TARGET
External Id: CHEMBL1931031
Name: Quantitative High-Throughput drug screen in 47 multiple myeloma cell lines against th...
Source: NCGC
Target: N/A
External Id: s-my-keats_OPM1-m4-1
Total 940, Current Page 1 of 94
1
2
3
4
5

 Synonyms

Irinotecan
7-ethoxyxanthone-3-carboxylic acid
Campto
(+)-Irinotecan
9H-Xanthene-3-carboxylic acid,7-ethoxy-9-oxo
MFCD01862255
(4S)-4,11-Diethyl-4-hydroxy-3,14-dioxo-3,4,12,14-tetrahydro-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl 1,4'-bipiperidine-1'-carboxylate
[1,4'-Bipiperidine]-1'-carboxylic acid, (4S)-4,11-diethyl-3,4,12,14-tetrahydro-4-hydroxy-3,14-dioxo-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinolin-9-yl ester
The content on this webpage is sourced from various professional data sources. If you have any questions or concerns regarding the content, please feel free to contact service1@chemsrc.com.
Top Suppliers:I want be here

Get all suppliers and price by the below link:

Irinotecan suppliers

Price: ￥452.4/50mg

Reference only. check more Irinotecan price

Related Compounds: More...
Dmac-BP
1685287-55-1
(E)-1-Fluoro-4-(1-phenylprop-1-en-2-yl)benzene
58662-10-5
1H,4H-3a,8a-Epoxyazulene, hexahydro-1,4-dimethyl-7-(1-methylethenyl)-, [1S-(1I+/-,3aI(2),4I+/-,7I+/-,8aI(2))]
10410-05-6
5,8-Dibromo-2,3-bis(5-(2-ethylhexyl)thiophen-2-yl)-6-fluoroquinoxaline
1643613-59-5
N-[(3aR,4R)-6-methoxy-3a-(2-methylprop-2-enyl)-1,2,3,4-tetrahydropyrrolo[1,2-a]indol-4-yl]-4-methylbenzenesulfonamide
1639953-82-4
N-[(3aR,4R)-6-methoxy-3a-prop-2-enyl-1,2,3,4-tetrahydropyrrolo[1,2-a]indol-4-yl]-4-methylbenzenesulfonamide
1639953-88-0
1-[(3-methoxyoxolan-3-yl)methyl]-1H-imidazol-2-amine
1700428-61-0
2-amino-4-(1-methyl-1H-pyrazol-4-yl)butanoic acid
1694624-42-4
2-amino-4-(1-methyl-1H-pyrazol-5-yl)butanoic acid
1695927-60-6
2-acetamido-4-(1-methyl-1H-pyrazol-4-yl)butanoic acid
1700025-94-0
Chemsrc provides Irinotecan(CAS#:97682-44-5) MSDS, density, melting point, boiling point, structure, formula, molecular weight etc. Articles of Irinotecan are included as well.>> amp version: Irinotecan

Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer

Copyright © 2026 ChemSrc All Rights Reserved